Advertisement

A Potential Approach to Gene Therapy of Cancer

  • Th. Friedmann
Conference paper
Part of the Research and Perspectives in Neurosciences book series (NEUROSCIENCE)

Abstract

Enormous progress has recently been made in the characterization of the biochemical and molecular events associated with the control of the mammalian cell cycle and with cell replication. Some of the normal cellular genes engaged in such regulatory functions have been shown to lead to, or be associated with, aberrant growth of cells and to the development of the neoplastic changes in the cells. There are at least two kinds of genes associated with the aberrant growth properties of tumor cells (Bishop 1991). Mutated, activated forms of the normal cellular proto-oncogenes are able to cause neoplastic transformation of cells by disrupting the normal controlled mechanisms of cell replication and growth. Their gene products can be imagined to provide positive stimuli to cellular growth. The presence of a single mutated allele is sufficient to cause cell transformation, and the continued presence and expression of the other, wild- type allele is insufficient for the maintenance of the normal cellular phenotype (Fig. 1). Potential therapeutic approaches toward the genetic reversal of these kinds of defects might include interference with translation of oncogene messenger RNAs by the introduction of anti-sense sequences or ribozymes specific for the oncogene transcript, the introduction of transdominant wild-type alleles or the introduction of non-allelic genes encoding functions that interfere with the transforming function of the oncogene (Fig. 2).

Keywords

Tumor Suppressor Gene Familial Cancer Syndrome Normal Cellular Growth Growth Suppress Function Normal Control Mechanism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bartek J, Iggo R, Lane DP (1990) Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5:893–899PubMedGoogle Scholar
  2. Bishop JM (1991) Molecular themes in oncogenesis. Cell 64:235–248PubMedCrossRefGoogle Scholar
  3. Bookstein R, Shew J-Y, Chen P-L, Scully P, Lee W-H (1990) Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated Rb gene. Science 247:712–715PubMedCrossRefGoogle Scholar
  4. Cavanee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL (1983) Expression of recessive alleles by chromosome mechanisms in retinoblastoma. Nature 305:779–784CrossRefGoogle Scholar
  5. Chang T, Yee J-K, Yeargin T, Friedman T, Haas M (1992) Suppression of acute lymphoblastic leukemia by the human p53 gene. Cancer Res 52:222–226Google Scholar
  6. Chen, P-L, Chen Y, Bookstein R, Lee W-H (1990) Genetic mechanisms of tumor suppression by the human p53 gene. Science 250:1576–1580PubMedCrossRefGoogle Scholar
  7. Cheng J, Haas M (1990) Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10:5502–5509PubMedGoogle Scholar
  8. Fearon ER, Vogelstein B (1990) A genetic model for colorectal carcinogenesis. Cell 61:759–767PubMedCrossRefGoogle Scholar
  9. Harris H (1988) The analysis of malignancy by cell fusion: the position in 1988. Cancer Res 48:3302–3306PubMedGoogle Scholar
  10. Haung H-J S, Yee J-K, Shew J-Y, Chen PI-L, Bookstein R, Friedmann T, Lee EY, HP, Lee W-H (1988) Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242:1563–1566CrossRefGoogle Scholar
  11. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427–428PubMedCrossRefGoogle Scholar
  12. Klein G (1987) The approaching era of the tumor suppressor genes. Science 238:1539–1545PubMedCrossRefGoogle Scholar
  13. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823PubMedCrossRefGoogle Scholar
  14. Lane DP, Benchimol S (1990) p53: oncogene or anti-oncogene? Genes Dev 4:1–8PubMedCrossRefGoogle Scholar
  15. Levine AJ (1990) The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology 177:419–426PubMedCrossRefGoogle Scholar
  16. Malkin D, Li FP, Strong LC, Fraumeni Jr JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238PubMedCrossRefGoogle Scholar
  17. Marshall CJ (1991) Tumor suppressor genes. Cell 64:313–326PubMedCrossRefGoogle Scholar
  18. Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ (1990) Negative growth regulation in a gliobastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87:6166–6170PubMedCrossRefGoogle Scholar
  19. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705–708PubMedCrossRefGoogle Scholar
  20. Stanbridge EJ (1990). Human tumor suppressor genes. Ann Rev Genet 24:615–657PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • Th. Friedmann

There are no affiliations available

Personalised recommendations